APC’s Scott Brunner and Tenille Davis are guests on the latest GameChangers Pharmacotherapy Podcast, where they cover facts and misinformation around compounded GLP-1s.
This week we were made aware that the Massachusetts Board of Pharmacy was questioning a compounder in the state for compounding what the pharmacy had incorrectly referred to as “oral semaglutide.”
We kept most of our Owner Summit sessions short and sweet, but some of our Saturday topics were too meaty to cover in 30 minutes. Here’s a quick roundup of three sessions.
Thanks to Pharmacists Mutual Insurance Company, the Pharmacy Compounding Foundation is offering up to two $2,500 scholarships to pharmacy students who have demonstrated commitment to a career in compounding pharmacy in the US.
Last week in a special edition of Compounding Connections, we shared a handful of new information and practice resources approved by the APC Board of Directors. It’s important for you to be aware of them, so we’re sharing again.
Me again, asking you for money. I do this a lot – too much, really – but the alternative is an underfunded APC that can’t protect your job, pharmacy, and patients. So I’ve got a deal for you.
APC’s Board this week approved minor revisions to its policy statement on Constructive Transfer of compounded controlled substance drugs. The statement was first adopted in 2010.
APC is releasing to its Pharmacy/Facility Members this week a Primer on Compounding Accreditations to assist them in determining accreditations they may wish to pursue.
APC’s Board of Directors has authorized two “best practices” documents aimed at helping APC members practice with utmost care and consistency.
Community pharmacies — defined as any pharmacy that dispenses medication to an outpatient, including both resident and nonresident pharmacies — are now required to report medication errors in California.
Through the generosity of Pharmacists Mutual Insurance Company, the Pharmacy Compounding Foundation is offering up to two (2) pharmacy students a scholarship valued at $2,500.
Before APC determines its position and prepares comments to FDA on the proposed rule, we want to hear from you.
If you haven’t read it yet, an excellent commentary was published in Medscape this week by a cardiologist and obesity specialist. He pushes back against rampant misinformation around compounded GLP-1s.
It’s been breathlessly anticipated for months, and this week it finally published: an FDA proposed rule regarding the Demonstrably Difficult to Compound list.
Since the program’s inception in 1997, 162 professionals have been honored as APC Fellows.
Long-time APC supporter Wedgewood Pharmacy, a compounder focused exclusively on animal health, is our newest 2024 Silver-level Corporate Patron.
In a draft report and plan for guidance documents released by FDA earlier this year, the agency indicated that it intends to issue guidance documents without a public notice and comment period.
Let’s say you’re APC. You get a call from a producer at a major news network saying that their celebrity medical doctor is doing a story on GLP-1 drugs and wants to include compounded GLP-1s in the piece.
The deadline to apply for 2024 induction is March 31, so review the information on the APC Fellows webpage and start your application now. The induction will take place at APC’s Compounders on Capitol Hill event in September.
There are a half-dozen “big deals” that APC will announce in the next three weeks, every one of them focused one way or another on assuring patient access, pharmacy/facility compliance, and practice efficiency.
OMB concluded their review of FDA’s proposed rule on Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A and 503B of the Federal Food Drug and Cosmetic Act and returned it with changes.
The U.S. Court of Appeals for the Fifth Circuit has accepted an amicus brief filed by APC in the case Zyla Life Sciences v. Wells Pharma.
This week, we updated our statement on rules governing compounding, what FDA guidance says about permissibility of compounding “essentially a copy” of an FDA-approved drug – and what those have to do with GLP-1s.
We’ve been busy this week on the state regulatory front, submitting comments on bills in Illinois and Maryland and sending our new statement on peptide compounding to all state boards of pharmacy. Here’s the lowdown.
Are you a pharmacist or technician committed to patient care through quality pharmacy compounding and the highest ethical and professional standards? If so, you should apply to be an APC Fellow.
Long-time APC booster Kalchem International has increased its support for APC to become a $25,000 Silver level Corporate Patron for this year. Hanszen Laporte law firm has also become a Bronze-level APC Corporate Patron this week.
There are only 25 spots left for the professional development event of the year for compounding pharmacy and facility owners and managers.
In an open letter released yesterday, drugmaker Eli Lilly had plenty to say about compounded GLP-1s, and – surprise! – not all of it accurate.
The APC Board of Directors has authorized release of a public statement, Understanding Law and Regulation Governing the Compounding of Peptide Products.
A new NCPA survey reveals local pharmacies are struggling to stay afloat after the January 1 implementation of the CMS DIR rule, requiring all pharmacy price concessions (i.e., DIR fees) to be assessed at the point of sale.
FOLLOW US
